#USA #Philadelphia #Siolta Therapeutics #STMC-103H #ADORED trial

Siolta Therapeutics to Present Groundbreaking Results at AAAAI 2026

Siolta Therapeutics is set to make waves at the upcoming American Academy of Allergy, Asthma and Immunology (AAAAI) annual meeting, scheduled from February 27 to March 2, 2026, in Philadelphia. The biotechnology company, known for its pioneering work in live biotherapeutic products (LBPs), has announced that its abstract detailing the one-year results from the Phase 2 ADORED clinical trial has been accepted for a late-breaking oral presentation. This marks a significant milestone for Siolta as they present findings related to STMC-103H, targeting at-risk infants for atopic conditions.

Presentation Details

The presentation will take place on February 28, 2026, at 2:00 PM EST during the Late Breaking Oral Abstract Session. The abstract, titled "STMC-103H Reduces Risk of Atopic Dermatitis and Food Allergy in At-Risk Infants: Results of the Phase 1b/2 Randomized, Double-Blind, Placebo-Controlled ADORED Trial," comes from extensive research involving infants susceptible to developing conditions like atopic dermatitis, food allergies, and allergic asthma.

Dr. Brian Vickery, a prominent figure in pediatric allergy and immunology and the Chief of the Division of Allergy/Immunology at Emory University’s Children's Healthcare, will present these vital findings. His expertise in the field lends credibility and insight to the results being shared.

Importance of the Findings

Research into atopic diseases has been growing rapidly, especially as these conditions become increasingly prevalent among infants. With STMC-103H, Siolta Therapeutics aims to address a critical niche in pediatric health by leveraging innovative live biotherapeutic products that focus on the human microbiome.

The ADORED trial was designed not just to observe results but to provide a foundation for further research in the field of allergy and immunology, potentially changing the landscape of treatment for atopic diseases in young children. The outcomes show promise for reducing the incidence of these diseases, which can significantly impact quality of life, especially if left unaddressed.

The acceptance of the abstract for late-breaking presentation underlines the significance of the findings within the clinical and research communities and indicates that Siolta’s research is among the most cutting-edge in the field. With results being published in a supplement to The Journal of Allergy and Clinical Immunology, and available online, this meeting presents an invaluable opportunity to share knowledge and advance understanding in a critical area of medicine.

About Siolta Therapeutics

Founded by leading scientists from the University of California, San Francisco, Siolta Therapeutics stands out in the biotech industry for its commitment to leveraging the human microbiome for preventing and treating immune-mediated diseases. As a clinical-stage company, Siolta is diligently working on developing first-in-class LBPs, with a keen focus on the maternal-infant axis, and aims to bring transformative treatments to pediatric care.

For more information about Siolta Therapeutics and their groundbreaking research, visit www.sioltatherapeutics.com.

This significant presentation at AAAAI 2026 represents more than just data; it symbolizes hope for many families facing the challenges of atopic diseases and epitomizes the importance of continued innovations in the field of biotechnology and pediatric healthcare.